EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baicalein Protects H9c2 Cardiomyoblasts Against LPS-Induced Inflammatory Injury by Modulating the NF-κB/NLRP3 Inflammasome Pathway and Mitochondrial ROS

Yi Lu, Zahra Zahid Piracha, Umar Saeed, Fangjun Luo

Iranian Journal of Pharmaceutical Research · 28.04.2026 · 25 (1)

DOI: 10.5812/ijpr-169689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 28.04.2026. Verfasst von Yi Lu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation, Sengong Hospital of Shaanxi Province, Xian, China. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sepsis-related cardiomyopathy is mainly induced by uncontrolled inflammation and mitochondrial oxidative damage triggered by endotoxins, especially those of Gram-negative bacteria. Lipopolysaccharide (LPS), an endotoxin, activates the Toll-like receptor 4/nuclear factor kappa B (TLR4/NF-κB) signaling pathway and the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, which further activates caspase-1 to process the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). Chronic activation of this signaling pathway is responsible for mitochondrial damage and loss of membrane potential. Baicalein, a flavonoid derived from the herbal plant Scutellaria baicalensis is well recognized for its anti-inflammatory and antioxidant properties, although its full modulation of the NF-κB/NLRP3 mitochondrial signaling pathway is not thoroughly understood.

Objectives

In this study, we assessed whether baicalein has a protective effect on H9c2 cardiomyoblasts against inflammatory and mitochondrial injury induced by LPS through regulation of inflammatory pathways involving NF-κB, the inflammasome, caspase-1 activity, cytokine expression, and oxidation.

Methods

H9c2 cells were pre-exposed to different baicalein concentrations (5 - 20 µM) and, after 1 hour, exposed to 1 µg/mL of LPS. Analysis included cell viability measurements by MTT assay, lactate dehydrogenase (LDH) release, and microscopic evaluation by phase-contrast microscopy. Expression levels of premature Nlrp3, Il1B, Il18, and Casp1 (0 - 4 h) were analyzed by real-time polymerase chain reaction (PCR). Protein levels of inflammasome and NF-κB pathway proteins were evaluated by immunoblot analysis. Activity of caspase-1 and cytokine secretion of IL-1β and IL-18 were evaluated by colorimetry and enzyme-linked immunosorbent assay (ELISA), respectively. Mitochondrial membrane potential (ΔΨm) was evaluated by staining with JC1 dye, and reactive oxygen species (ROS) levels were evaluated by fluorescence with DCFH2DA; N-acetylcysteine (NAC) was used as an antioxidant positive control.

Results

LPS strongly elevated the transcription of Nlrp3 and Il1b at 2 hours, in addition to enhancing protein expression of NLRP3, activity of caspase-1, and secretion of IL-1β and IL-18. Underlying these pro-inflammatory responses were mitochondrial depolarization, augmented ROS production, diminished cell survival, and cytotoxicity. Prior administration of baicalein mitigated NF-κB activation, diminished priming of the inflammasome response at both transcriptional and protein levels, and decreased caspase-1 activity and secretion of the cytokines. Moreover, baicalein maintained mitochondrial membrane potential and diminished ROS within the cells, comparable to NAC, and improved cellular viability and morphology Conclusions: Baicalein confers substantial protection against LPS-induced inflammatory and oxidative damage in H9c2 cardiomyoblasts by concurrently suppressing NF-κB activation, mitigating NLRP3 inflammasome signaling, curbing caspase-1–driven cytokine maturation, and stabilizing mitochondrial function through reduction of ROS. These findings identify baicalein as a promising candidate for targeting the ROS-inflammasome axis in sepsis-associated cardiac dysfunction and related inflammatory cardiac disorders.

Schlagwörter

Stichwörter der Autor:innen

Antioxidant TherapyBaicaleinCardiomyocyte InflammationCaspase-1H9c2 CardiomyoblastsIL-18IL-1βLipopolysaccharideMitochondrial Membrane PotentialNF-κB SignalingNLRP3 InflammasomeOxidative StressReactive Oxygen SpeciesSepsis-associated Cardiomyopathy

Autor:innen und Institutionen

  • Department of Rehabilitation, Sengong Hospital of Shaanxi Province, Xian, China.
  • Faculty of Rehabilitation and Allied Health Sciences, Riphah International University, Islamabad, Pakistan.
  • Széchenyi István University, Győr, Hungary.
  • Institute of Graduate Studies and Research, Cyprus International University, Nicosia, Cyprus.
  • Korea University College of Health Sciences, Korea University , Seoul, South Korea.
  • Department of Emergency, Hanzhong Hospital of Traditional Chinese Medicine, Hanzhong, China.

Zitieren

APA

Lu, Y., Zahid Piracha, Z., Saeed, U., & Luo, F. (2026). Baicalein Protects H9c2 Cardiomyoblasts Against LPS-Induced Inflammatory Injury by Modulating the NF-κB/NLRP3 Inflammasome Pathway and Mitochondrial ROS. Iranian Journal of Pharmaceutical Research, 25(1). https://doi.org/10.5812/ijpr-169689

Vancouver

Lu Y, Zahid Piracha Z, Saeed U, Luo F. Baicalein Protects H9c2 Cardiomyoblasts Against LPS-Induced Inflammatory Injury by Modulating the NF-κB/NLRP3 Inflammasome Pathway and Mitochondrial ROS. Iranian Journal of Pharmaceutical Research. 2026;25(1). doi:10.5812/ijpr-169689

BibTeX
@article{Lu2026,
  author = {Lu, Yi and Zahid Piracha, Zahra and Saeed, Umar and Luo, Fangjun},
  title = {Baicalein Protects H9c2 Cardiomyoblasts Against LPS-Induced Inflammatory Injury by Modulating the NF-κB/NLRP3 Inflammasome Pathway and Mitochondrial ROS},
  journal = {Iranian Journal of Pharmaceutical Research},
  year = {2026},
  volume = {25},
  number = {1},
  doi = {10.5812/ijpr-169689}
}
Kostenlos starten →